Fig. 3From: Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatmentMeta-analysis forest plot with a fixed-effect model showing the disease control rate (DCR), which is 73 % with a 95 % CI of 65–80 %. The total number of individuals included in the analysis was 154. I2 = 0.000Back to article page